BIOMARKER:

IGH mutation

Entrez ID:

Related biomarkers:

‹

›

IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	ibrutinib Sensitive: A2 - Guideline	ibrutinib Sensitive: A2 - Guideline
IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	obinutuzumab Sensitive: A2 - Guideline	obinutuzumab Sensitive: A2 - Guideline
IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	venetoclax + obinutuzumab Sensitive: A2 - Guideline	venetoclax + obinutuzumab Sensitive: A2 - Guideline
IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	FCR Sensitive: A2 - Guideline	FCR Sensitive: A2 - Guideline
IGH mutation IGH mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	IGH mutation IGH mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	ibrutinib Sensitive: B - Late Trials	ibrutinib Sensitive: B - Late Trials
IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	rituximab + idelalisib Sensitive: B - Late Trials	rituximab + idelalisib Sensitive: B - Late Trials
IGH mutation IGH mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	IGH mutation IGH mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	FCR Sensitive: C3 – Early Trials	FCR Sensitive: C3 – Early Trials
IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	IGH mutation IGH mutation	Chronic Lymphocytic Leukemia CLL	iFCG Sensitive: C3 – Early Trials	iFCG Sensitive: C3 – Early Trials